Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in moderate to severe COPD
NCT06547333Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2024
- Primary completion
- Apr 2032
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of stapokibart in chronic obstructive pulmonary disease (COPD), sponsored by CSPC ZhongQi Pharmaceutical Technology. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06547333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547333.